Biomaterials used to Deliver Drugs for Colon Cancer Management

Abstract: Despite the major advancements in cancer treatment, colon cancer (CC) is still one of the most lethal malignancies worldwide. Among various type of cancer, it is the third largest prevailing kind of cancer affecting both men and women equally. Metastatic development is particularly common in individuals with advanced stages and frequently associated with subpar response of chemotherapy and severe morbidity. The unfavorable effects of intense chemotherapy on normal cells and emergence of multidrug resistance are the two main reasons for treatment failure. Recent research in nanotechnology enables the use of advanced natural and synthetic biomaterials alone or in combination to target cancer cells with anticancer medications without affecting healthy cells. Anticancer drug laden nanocarriers improve the drug distribution, bioavailability and accumulation of cytotoxic therapeutic concentration at tumor site along with reduced side effects. Additionally, upon oral administration, polymeric vehicles shield the medication from premature release, degradation in upper gastrointestinal tract and facilitate controlled release at cancerous site of colon. Here, we primarily focus on the present situation and possible advantages of polymeric biomaterials either owned or in conjunction with other therapeutics to develop ideal drug carrier systems to treat colon carcinoma.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Drugs
Published
2024-12-26
DOI
https://doi.org/10.2174/012212697x299780240905141609
Citations
2
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.35
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Biomaterials used to Deliver Drugs for Colon Cancer Management

Manu Sharma, Namita Badoniya
2 citations
Clinical Cancer Drugs
Nanoparticle-Based Drug Delivery
0.35
article

Biomaterials used to Deliver Drugs for Colon Cancer Management

Manu Sharma, Namita Badoniya
article en
2 citations

Abstract

Abstract: Despite the major advancements in cancer treatment, colon cancer (CC) is still one of the most lethal malignancies worldwide. Among various type of cancer, it is the third largest prevailing kind of cancer affecting both men and women equally. Metastatic development is particularly common in individuals with advanced stages and frequently associated with subpar response of chemotherapy and severe morbidity. The unfavorable effects of intense chemotherapy on normal cells and emergence of multidrug resistance are the two main reasons for treatment failure. Recent research in nanotechnology enables the use of advanced natural and synthetic biomaterials alone or in combination to target cancer cells with anticancer medications without affecting healthy cells. Anticancer drug laden nanocarriers improve the drug distribution, bioavailability and accumulation of cytotoxic therapeutic concentration at tumor site along with reduced side effects. Additionally, upon oral administration, polymeric vehicles shield the medication from premature release, degradation in upper gastrointestinal tract and facilitate controlled release at cancerous site of colon. Here, we primarily focus on the present situation and possible advantages of polymeric biomaterials either owned or in conjunction with other therapeutics to develop ideal drug carrier systems to treat colon carcinoma.

Clinical Cancer DrugsVol. 11
Banasthali University (IN)
Good health and well-being
Openalex Percentile: Top 42%
Nanoparticle-Based Drug Delivery
0.35
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.